关键词
阿托吉泮 卡瑞利珠单抗 比替拉韦 多替拉韦 疫苗 特瑞普利单抗 苏帕鲁肽 依拉环素 艾克利单抗
①The Lancet:Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
临床试验:降钙素基因相关肽 (CGRP)受体拮抗药阿托吉泮(Atogepant)用于慢性偏头痛的一项随机、双盲、安慰剂对照的Ⅲ期试验
DOI: 10.1016/S0140-6736(23)01049-8
②The Lancet:Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
临床试验:卡瑞利珠单抗联合利沃昔尼与索拉非尼用于不可切除肝细胞癌的比较(CARES-310):一项随机、开放标签、国际性Ⅲ期研究
DOI: 10.1016/S0140-6736(23)00961-3
③The Lancet HIV:Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
临床试验:比替拉韦、恩曲他滨和丙酚替诺福韦与多替拉韦、恩曲他滨和富马酸替诺福韦二吡呋酯用于HIV-1和乙型肝炎(HBV)合并感染的比较(ALLIANCE):一项双盲、多中心、随机对照、3期非劣效性试验
DOI: 10.1016/S2352-3018(23)00151-0
④The Lancet Infectious Diseases:Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
疟疾传播阻断疫苗Pfs230D1-EPA和Pfs25-EPA在马里健康成人中的应用:一项Ⅰ期随机对照试验
DOI: 10.1016/S1473-3099(23)00276-1
⑤EClinicalMedicine:Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis
综述:当前药物用于难治性或不明原因慢性咳嗽的有效性和安全性的系统综述和网络荟萃分析
DOI: 10.1016/j.eclinm.2023.102100
⑥EClinicalMedicine:A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
特瑞普利单抗联合NCRT用于局部晚期食管鳞癌的有效性和安全性Ⅱ期临床试验(NEOCRTEC1901)
DOI: 10.1016/j.eclinm.2023.102118
⑦人源化长效GLP-1R激动剂苏帕鲁肽(Supaglutide)用于肥胖症的适应症获国家药监局临床试验默示许可
⑧靶向乙型肝炎病毒(HBV)的小干扰RNA(siRNA)药物TQA3038的临床试验申请获CDE受理,拟开发用于慢性乙型肝炎
⑨全球首个氟环素类抗菌药物依拉环素(依嘉)在中国首张处方落地,用于包括临床常见多重耐药菌在内的革兰阴性菌、革兰阳性菌、厌氧菌等所引起的感染
⑩靶向细胞表面蛋白CSF-1R的单克隆抗体艾克利单抗(Axatilimab)用于慢性移植物抗宿主病(GVHD)的II期AGAVE-201研究达到主要终点
科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴!
联系客服